A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Breast Cancer
- Gastric Cancer
- Renal Cell Carcinoma
- Ovarian Cancer
- Cholangiocarcinoma
- Bladder Urothelial Carcinoma
- Pancreatic Adenocarcinoma
- Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Head and Neck Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Other Solid Tumors
- Diffuse Large B-cell Lymphoma (DLBCL)
- Mantle Cell Lymphoma
- Indolent B-cell Lymphomas
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytic Lymphoma
- Waldenstrom's Disease
- Marginal Zone Lymphoma
- Mucosa Associated Lymphoid Tissue
- Small Lymphocytic Leukemia
Interventions
- DRUG: CDX-1140
- DRUG: CDX-301
- DRUG: pembrolizumab
- DRUG: Chemotherapy
Sponsor
Celldex Therapeutics
Collaborators